Shares of Xeris Biopharma Holdings gained after the company raised its revenue guidance for 2025, driven by the performance of its Recorlev treatment. The stock rose 9.5% to $7.90 on Thursday. Shares ...
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient careLONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ...
Recordati Rare Diseases Canada Inc. announced today the Canadian product availability of ISTURISA® (osilodrostat) for the ...
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the companies’ respective drug applications. Sanofi revealed Dec. 24 that the ...
Years after the first reports of Havana Syndrome emerged, U.S. officials have obtained and are testing a device that could ...
The FDA has approved pergolide tablets (Zygolide; Dechra) for controlling clinical signs associated with pituitary pars intermedia dysfunction (PPID) in horses, also known as equine Cushing disease.
Treatment with atumelnant resulted in rapid, sustained lowering of androstenedione (in all eight patients that completed the fourth cohort). Seven out of these eight patients continued to maintain ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The same drug is under FDA ...
Verywell Health on MSN
How Is Huntington's Disease Treated?
Huntington's disease symptom control relies on medications for involuntary movements, mood, and psychiatric symptoms, but ...
Verywell Health on MSN
What Are the Symptoms of Huntington's Disease?
Symptoms caused by Huntington's disease include loss of motor control, involuntary movements, dementia, mood disorders, and psychiatric though disturbances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback